BioMed Valley Discoveries recently shared their latest findings at AACR 2022 regarding combining ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors to treat MAPK pathway altered tumors. As part of this work, Theralink’s RPPA technology was used to understand how administration of the first-in-class small molecule inhibitor of ERK1/2, ulixertinib (BVD-523), combined with the CDK4/6 inhibitor palbociclib, … Continue reading Research Highlight: RPPA gives a deep look at response to new combination therapy

Detecting activated biomarker signals is challenging with traditional IHC In clinical oncology, immunohistochemistry (IHC) is often used to determine the presence or absence of protein biomarkers. Clinical scientists will section and mount tumor samples, then stain using a primary antibody for the target biomarker. Because detection is done on a single section of tissue at … Continue reading RPPA: Detecting Protein Phosphorylation When IHC Just Doesn’t Cut It

Experiments of all shapes and sizes In biopharma translatability of data is a serious concern, as a wide variety of sample types and experimental designs are used depending on the stage of the developmental pipeline. Pre-clinical research and discovery often use cell-based or animal-based models to test potential therapeutics, as these models allow for easier … Continue reading Translatability: RPPA from discovery to patient care

Long ago in a faraway land, identifying phosphoproteins in formalin-fixed paraffin-embedded (FFPE) tissue was really really difficult. Even the great immunohistochemistry (IHC) could not surmount this mountain. Then came a hero among heroes, Reverse Phase Protein Array (RPPA). The End. Just kidding! Well, actually not really. It is true that the reason RPPA was developed … Continue reading Come as you are: Sample prep with RPPA

Dosage is one of the key components of an effective application of therapeutic drugs in patients. Too low a dosage may lead to a poor response in the patient. However, unnecessarily high dosage is wasteful and could be toxic to the patient. Today’s blog will focus on how drug developers decide on the proper dosage. … Continue reading MTD vs MED: A Tale of Two Dosages

Recently, after 2 years of virtual conferences and online connections, Theralink had the chance to go to the 2022 American Association for Cancer Research (AACR) annual meeting in person. We caught up with our representatives Senior Research Specialist, Brian Corgiat, and Senior Director of Biopharma Commercial operations, Michael Fanelli. What was the main goal of … Continue reading Reflections on the American Association for Cancer Research (AACR) 2022 Annual Meeting

Previously, we discussed how proteomics is a better measure of the pharmacodynamic effects of target inhibition in drug development. There are a few ways to analyze protein levels and function across patients samples including Mass Spectrometry, ELISA, and our specialty, Reverse Phase Protein Array (RPPA). Today we’ll be giving an overview and comparison of a … Continue reading This or That: RPPA vs Mass Spectrometry vs ELISA

Mitochondria is the Powerhouse of the Cell. They are also involved in many signaling pathways including cell death, innate immunity, etc.

Chimeric Antigen Receptor (CAR) therapy is the modification of a patient’s immune cells so that they target cancer cells.  In the case of T-cells and CAR-T therapy, cells are taken from a patient’s blood and modified to include a special receptor (CAR receptor) that binds to a specific protein on the patient’s cancer cells. Scientists … Continue reading Theralink Enhanced Vehicles – CAR-T and CAR-NK

Today we will be diving into cross-talk between the Big 3 canonical pathways in cancer research: AKT-mTOR, Ras-MAPK, and JAK-STAT. Up to 70% of all human tumors have upregulated mTORC1 function and several oncogenes and/or tumor suppressors have been linked to mTOR signaling. Consequently, most cancer therapeutic strategies target mTOR signaling by way of AKT … Continue reading The Big 3: AKT-mTOR, Ras-MAPK, JAK-STAT

Today let’s look into Immuno-oncology (I/O)- particularly using PD1/PDL1 as a case study! With several companies turning to I/O and immuno-therapy for cancer therapeutics, we offer several upstream and downstream targets of interest for patient stratification! One frequent question from our clients is that: “It’s a cool technology, but how can it benefit my PD-1/PD-L1 … Continue reading Into the I/O: A immuno-oncology PD1/PDL1 Case Study

Theralink Technologies is a molecular profiling and precision medicine oncology company specializing in patented, biomarker assay services. We use quantitative Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) technology to support therapeutic development from discovery through clinical trials. This patented technology offers Next Generation Proteomics (NGP)TM services that produce in-depth broad-scale signalling analysis … Continue reading The Theralink Assay